Shionogi
Clinical trials sponsored by Shionogi, explained in plain language.
-
New antibiotic shows promise for newborns with dangerous infections
Disease control CompletedThis study looked at how the antibiotic cefiderocol works in hospitalized infants under 3 months old with suspected or confirmed gram-negative bacterial infections. Researchers measured drug levels in the blood and checked for side effects in 30 babies. The goal was to find the r…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New antibiotic shows promise for kids with tough infections
Disease control CompletedThis study tested the safety and how the body processes the antibiotic cefiderocol in hospitalized children aged 3 months to 18 years with serious bacterial infections. The goal was to see if the drug is safe and how it works in the body. 53 children participated, and the study i…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New COVID pill shows promise in early trial
Disease control CompletedThis completed Phase 2 study tested an oral antiviral drug called S-892216 in 282 adults with mild-to-moderate COVID-19. Participants took either the drug or a placebo tablet for a short time. The main goal was to see if the drug could lower the amount of virus in the nose and th…
Phase: PHASE2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New COVID pill shows promise in large trial
Disease control CompletedThis large Phase 3 study tested an antiviral pill called S-217622 in over 2,000 adults with mild to moderate COVID-19 who were not hospitalized. Participants started the drug within 3 days of symptoms. The main goal was to see if the drug shortens symptom duration compared to a p…
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
New COVID-19 vaccine shows promise in large trial
Prevention CompletedThis phase 3 trial tested a new COVID-19 vaccine called S-268019-b in nearly 10,000 adults. Participants received either the vaccine or a placebo to see if it could prevent COVID-19. The study looked at how many people got sick after vaccination and checked for safety and immune …
Phase: PHASE3 • Sponsor: Shionogi • Aim: Prevention
Last updated Jun 27, 2026 08:00 UTC
-
Scientists hunt for biological clues to how ALS drug affects the body
Knowledge-focused CompletedThis study follows about 74 adults with ALS who have already decided to take the drug Edaravone (Radicava). Researchers collect blood and urine samples over 24 weeks to measure various biomarkers—molecules that might show how the drug affects oxidative stress, inflammation, and n…
Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Liver impairment drug study completed: what happens to BPN14770?
Knowledge-focused CompletedThis study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects.…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Kidney disease may change how this drug works
Knowledge-focused CompletedThis study looked at how the drug BPN14770 moves through the body in people with severe kidney problems compared to healthy people. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if kidney function affects how the drug is pr…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
New drug S-740792 tested in healthy volunteers for first time
Knowledge-focused CompletedThis early-phase trial tested the safety and processing of a new drug called S-740792 in 99 healthy adults. Participants received single or multiple doses of the drug as a liquid or tablet, and some received a placebo. The goal was to gather safety data and understand how the bod…
Phase: PHASE1 • Sponsor: Shionogi • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC